Pembrolizumab trough concentration monitoring and association with outcomes in advanced no

31 patients with advanced non-small cell lung cancer receiving pembrolizumab monotherapy were followed for two years in a prospective therapeutic drug monitoring study. Serial trough concentration measurements were taken at five timepoints over the first year, with baseline clinicopathologic variables recorded and outcomes assessed. Pembrolizumab levels increased significantly over time, with higher late-treatment concentrations associated with improved clinical outcomes and a greater number of immune-related adverse events.

Use Cases

• Modeling pembrolizumab pharmacokinetics over time based on serial trough concentration measurements.
• Investigating associations between drug exposure and clinical outcomes like tumor response or survival.
• Analyzing correlations between pembrolizumab levels and immune-related adverse events across organ systems.
• Identifying baseline predictors, such as albumin levels and comorbidities, of higher drug concentrations.

Strengths

• Prospective study design with serial measurements at five defined timepoints over one year.
• Two-year patient follow-up for treatment outcome assessment.
• Includes baseline clinicopathologic and serologic variables for predictive modeling.

Limitations

• Small cohort of 31 patients, which may limit statistical power and generalizability.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale ML tasks.

Provenance

Source

Author: Ioannis P. Trontzas. Platform: figshare.

Collection Method

Prospective therapeutic drug monitoring study using a commercial ELISA kit for measurement.

Time Range

Data collection spans two years of patient follow-up.

Freshness

Last updated 2026-04-30 11:00:04; freshness should be verified.

Geography

null